NCCN guidelines indicate rusfertide for patients who are intolerant to phlebotomy or who receive frequent phlebotomy, regardless of risk status.
Related to this article
The FDA designation is for LYT-200 plus a hypomethylating agent for relapsed/refractory high-risk myelodysplastic syndromes.
The application for bezuclastinib in advanced systemic mastocytosisis is supported by data from the APEX trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Survey Reports Widespread Adoption of Bispecifics in Community Oncology
2
Life-Years Saved Captures Gains—and Gaps—in Blood Cancer Treatment
3
Prioritizing BCMA-Targeted Therapies in Early Relapsed Multiple Myeloma
4
Dr Lepor on Rise of Precision Strategies to Address Early Prostate Cancer
5